Howard Robin

“In July, we achieved yet another important milestone in Nectar with the initiation of the Global Zenith AD Program, Phase 3 AD Program for Respeg Alvis Lucan, also known as Respeg, in moderate to severe ectopic dermatitis.”

“We are exceptionally proud of the progress we've made at the company. The data we've reported over the last year from our Phase 2B studies in ectopic dermatitis and alopecia areata demonstrate that ResBeg could produce clinically meaningful outcomes in two distinct autoimmune and inflammatory disease settings.”

“We're very pleased this morning to share the exciting top-line results from the 16-week extension period of our ongoing Resolv AA phase 2b study, which is evaluating Respeg aldous leucan in patients with severe to very severe alopecia areata.”

“2025 was a pivotal year for Nektar Therapeutics, and we continue to build on the success with significant progress in 2026. In 2023, we unveiled our plans to focus on the advancement of our immunology and inflammation pipeline programs, which center around the biology of T regulatory cells.”

“The second quarter of 2025 was transformative for Nektar. In June, we reported highly compelling initial data in atopic dermatitis for our lead clinical program, rezpegaldesleukin, also known as REZPEG.”